Department of Clinical Investigation, National Hospital Organization Kochi Hospital, 1-2-25 Asakuranishimachi, Kochi-city, Kochi, 780-8507, Japan.
Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, 1-2-25 Asakuranishimachi, Kochi-city, Kochi, 780-8507, Japan.
Cancer Immunol Immunother. 2022 Feb;71(2):365-372. doi: 10.1007/s00262-021-02994-5. Epub 2021 Jun 25.
Tumor-related eosinophilia may have extended survival benefits for some cancer patients. However, there has been no report on the prognosis difference between eosinophilic pleural effusion (EPE) and non-EPE in lung cancer patients. Our study aimed to investigate the prognosis difference between EPE and non-EPE due to lung cancer.
We retrospectively reviewed patients diagnosed with lung cancer who presented with malignant pleural effusion (MPE) between May 2007 and September 2020 at the National Hospital Organization Kochi Hospital. EPE is defined as pleural fluid with a nucleated cell count containing 10% or more eosinophils.
A total of 152 patients were included: 89 were male (59%). The median age was 74.4 years (range 37-101), and all patients were pathologically shown to have MPE. Most patients (140; 92%) had an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0/1. Twenty patients had EPE. The median overall survival (OS) of all 152 lung cancer patients with MPE was 298 days. The median OS of the patients with EPE was 766 days, and the median OS of the patients with non-EPE was 252 days. Kaplan-Meier univariate analysis showed that lung cancer patients with EPE had a significantly better prognosis than patients with non-EPE (P < 0.05). Cox proportional regression analysis showed that EPE, ECOG PS, sex, and the neutrophil-to-lymphocyte ratio in the serum (sNLR) may be independent prognostic factors affecting survival in patients with MPE.
Lung cancer patients with EPE have a better prognosis than those with non-EPE.
肿瘤相关性嗜酸性粒细胞增多可能会延长某些癌症患者的生存获益。然而，目前尚无关于肺癌患者嗜酸粒细胞性胸腔积液（EPE）和非嗜酸粒细胞性胸腔积液（non-EPE）预后差异的报道。本研究旨在探讨肺癌患者 EPE 和 non-EPE 之间的预后差异。
我们回顾性分析了 2007 年 5 月至 2020 年 9 月期间在日本国立医院组织高知医院就诊的诊断为肺癌并伴有恶性胸腔积液（MPE）的患者。EPE 定义为胸腔积液中含有 10%或更多嗜酸性粒细胞的有核细胞计数。
共纳入 152 例患者：男性 89 例（59%）。中位年龄为 74.4 岁（范围 37-101 岁），所有患者均经病理证实为 MPE。大多数患者（140 例，92%）的东部肿瘤协作组（ECOG）体能状态（PS）为 0/1。20 例患者为 EPE。所有 152 例肺癌合并 MPE 患者的中位总生存期（OS）为 298 天。EPE 患者的中位 OS 为 766 天，non-EPE 患者的中位 OS 为 252 天。Kaplan-Meier 单因素分析显示，EPE 的肺癌患者预后明显优于 non-EPE 患者（P<0.05）。Cox 比例风险回归分析显示，EPE、ECOG PS、性别和血清中性粒细胞与淋巴细胞比值（sNLR）可能是影响 MPE 患者生存的独立预后因素。
EPE 的肺癌患者预后优于 non-EPE 的患者。
Zotero 插件
